EP 235: Inside Alzheimer’s disease: Blood biomarkers and predicting symptoms with Suzanne Schindler

EP 235: Inside Alzheimer’s disease: Blood biomarkers and predicting symptoms with Suzanne Schindler

by Sano Genetics

Life & Natural Systems Medicine & Health MKJNeurology and clinical neurophysiologyMKJDAlzheimer’s, dementia, Parkinson’s disease and other neurodegenerative diseases
🎙 Sano Genetics 👥 942 📅 April 16, 2026 ⏱ 40 min 👁 43 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

Alzheimer's diseaseblood biomarkersp-tau217APOEsymptom prediction

Summary

In this episode of The Genetics Podcast, host Patrick Short interviews Dr. Suzanne Schindler, an Associate Professor of Neurology at Washington University in St. Louis, about the latest advances in Alzheimer’s disease research, particularly focusing on blood-based biomarkers. Dr. Schindler explains the distinction between Alzheimer’s disease and dementia, emphasizing that Alzheimer’s is defined by the presence of amyloid plaques and tau tangles. She discusses the role of the APOE gene, particularly the epsilon 4 allele, in increasing the risk of developing amyloid plaques earlier in life. The conversation highlights the significance of phosphorylated tau 217 (p-tau217) as a blood biomarker that changes about 15 years before symptom onset, allowing for earlier detection and staging of the disease. Dr. Schindler introduces ‘clock models’ that use biomarker trajectories to estimate when symptoms may begin, which could improve clinical trial design and patient care. She also touches on sex differences in tau pathology, rare cases where amyloid and tau pathology do not align, and the potential of combining biomarkers with clinical phenotyping. The discussion covers therapeutic strategies, including amyloid-targeting and tau-targeting treatments, and the challenges of targeting inflammation. The episode concludes with thoughts on expanding biomarkers beyond p-tau217 and integrating them into clinical practice.

201 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of the information is high, as it provides a comprehensive overview of current research on blood biomarkers for Alzheimer’s disease, with specific insights from a leading researcher. The argumentation is solid, grounded in peer-reviewed studies and clinical experience. Dr. Schindler presents complex concepts clearly, supporting her points with data and examples, such as the ‘clock models’ and the case of Doug Whitney. The discussion is balanced, acknowledging uncertainties and open questions in the field.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is strong, with references to recent publications in Nature Medicine and Nature Communications. The quality of sources is high, as Dr. Schindler is an expert in the field. The title accurately reflects the content, focusing on blood biomarkers and symptom prediction. The episode is well-structured, with clear explanations and appropriate caveats about the limitations of current biomarkers.

151 words

Title / Content Match

The title accurately reflects the content, focusing on blood biomarkers and symptom prediction in Alzheimer's disease.

Quality & Reliability

8/10

The discussion is led by an expert in the field, referencing recent peer-reviewed studies. The content is well-structured and scientifically grounded, though it is an interview format with some speculative elements.

Chapters

Cited Sources

  • Phosphorylated tau217 study — Discussed in the episode as the study using plasma p-tau217 trajectories to estimate when Alzheimer's symptoms may begin.
  • MTBR-tau243 study — Mentioned as a more specific marker of tau pathology and Alzheimer's symptoms.

Concurring Sources

  • Phosphorylated tau217 study — The study discussed in the episode, supporting the use of p-tau217 for predicting symptom onset.
  • MTBR-tau243 study — Mentioned as a more specific marker of tau pathology, consistent with the discussion.

Contribution & Novelties

The episode provides an expert perspective on the use of blood biomarkers, particularly p-tau217, to predict the onset of Alzheimer’s symptoms, highlighting the concept of ‘clock models’ that align biomarker trajectories. It offers insights into the interplay between amyloid and tau pathology, the role of APOE, and potential implications for clinical trials and patient care.

Pour aller plus loin :

106 words

Radar Profile

The radar profile shows high scores in quality and reliability, with slightly lower scores in quantity and technical level, indicating a focused, expert-led discussion with strong scientific backing.

Reliability 8/10